GEN Exclusives

More »

GEN News Highlights

More »
Dec 10, 2010

Serodus Licenses Potential Heart Failure Therapy from Roche

  • Serodus has licensed a selective serotonin-4 (5-HT4) antagonist called RO1160367 from Roche for the treatment of heart failure. The molecule is reportedly ready to enter Phase II studies.

    Under the agreement Serodus will receive the full preclinical and clinical documentation for RO1160367, which will be called SER101. In return, Roche will get an up-front payment as well as be entitled to development, regulatory, and commercial milestone fees. Roche is also eligible to receive royalties on sales of products commercialized under the license.

    Serodus has been granted the exclusive development, manufacturing, and worldwide marketing and sale rights. The firm is allowed to sublicense the drug, and, in certain cases, Roche has the right to regain the product.

    Researchers at the University of Oslo discovered that muscle cells in failing cardiac ventricles express 5-HT4 receptors as a response to this condition. The effect of 5-HT4antagonists in heart failure has been demonstrated in rat and man, according to Roche and Serodus.

    Remarking on the in-licensing, Eva Steiness, M.D., Serodus CEO, says, “This agreement will enable Serodus to move its heart failure program directly into the clinic without waiting for our own preclinical development.”

    Serodus has one other clinical-stage compound and a preclinical candidate, SER102, for postsurgical atrial fibrillation. SER100 is an opioid-1 that was acquired from Zealand Pharma this year. The results from previous studies in chronic and acute heart failure indicate that the drug has potential to treat isolated systolic hypertension, which Serodus will pursue in a Phase IIa trial.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »